Safety and efficacy of pregabalin in patients with central post-stroke pain

@article{Kim2011SafetyAE,
  title={Safety and efficacy of pregabalin in patients with central post-stroke pain},
  author={Jong S. Kim and Guy M Bashford and T. Kevin Murphy and Andrew Martin and Raymond Cheung},
  journal={PAIN},
  year={2011},
  volume={152},
  pages={1018-1023}
}
Pregabalin has demonstrated efficacy in several forms of neuropathic pain, but its long-term efficacy in central post-stroke pain (CPSP) is unproven. We evaluated the efficacy and safety of pregabalin versus placebo in patients with CPSP. A 13-week, randomized, double-blind, multicenter, placebo-controlled, parallel group study of 150 to 600 mg/day pregabalin was conducted in patients aged ≥18 years with CPSP. The primary efficacy endpoint was the mean pain score on the Daily Pain Rating Scale… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

clinical trials : IMMPACT recommendations

  • R Freeman, E Durso-Decruz, B Emir
  • PAIN
  • 2010

diabetic neuropathy and postherpetic neuralgia : differences in demographic data and sensory symptoms

  • F Benedetti, A Pollo, L Lopiano, M Lanotte, S Vighetti, I Rainero
  • 2009

: a randomized , double - blind , placebo - controlled , cross - over , multi - center study

  • P Hansson
  • 2008

Similar Papers

Loading similar papers…